1. Introduction to Dendritic Cell Cancer Vaccine
1.1 Dendritic Cell Cancer Vaccine Historical Development
1.2 Dendritic Cell Vaccines: A New Era for Cancer Immunotherapy
2. Relevance of Dendritic Cells in Immune System & Cancer Therapy
2.1 Dendritic Cell: Integral Part of Human Immune System
2.2 Effects of Cancer on Dendritic Cell Mediated Immunity
3. Dendritic Cell Cancer Vaccines: Mechanism of Action
3.1 Manufacturing of Dendritic Cell Vaccines
3.2 Mechanism of Dendritic Cell Vaccine against Cancer Cells
4. Dendritic Cell Cancer Vaccine In Combination Therapy
4.1 Radiotherapy
4.2 Monoclonal Antibodies
5. Research & Technological Collaborations for Advancing the Dendritic Cell Immunotherapy Market
5.1 UCLA Researchers Re-Defying Research for Dendritic Cell Immunotherapy
5.2 Personalized Dendritic Cell Vaccine Improving the Overall Survival Rate of Glioblastoma Patients
5.3 Cutting-Edge Grant Approval for Dendritic Cell Immunotherapy Market Advancement in UCLA
5.4 Dendritic Cell Cytokines Leading to Increased Clinical Outcome in Case of Different Cancer Types
5.5 Human Telomerase Reverse Transcriptase (hTERT)-Expressing Autologous Dendritic Cells (hTERT-DCs) Efficiency in Case of Acute Myeloid Leukemia
5.6 APAC Biotech Company to Deliver Dendritic Cell Immunotherapy in India
5.7 Nimbus Therapeutics & Celgene to Work Together for Expanding the Applications of Dendritic Cell Therapy
5.8 Specific Dendritic Cell Vaccines ATTAC Study Result for the Treatment of Glioblastoma
5.9 Bristol Myers Squibb & UbiVac Announces Collaboration for Dendritic Cell-Targeted Microvesicle (DPV-001)
5.10 Cancer Research UK & VOLT to Conduct First-in-Human Trial for Dendritic Cell Therapy
5.11 University of California San Diego Research Work for Confirming the Efficacy of Dendritic Cell Cancer Vaccines
5.12 Interleukin-32 Dendritic Cell Therapy Provoking Promising Strategy Treatment
5.13 Elicio Therapeutics & Moffitt to Evaluate the Combinational Outcomes for AMP-CD19 & CD19 CAR-T Cells
5.14 Dendritic Cell Immunotherapy Discovery as Novel Guards for Immune System
5.15 Non-Small Cell Lung Cancer Treatment by Autologous Dendritic Cancer Cell Vaccines
5.16 Dendritic Cell Immunotherapy Preliminary Reports for Solid & Haematological Malignancies
7. Dendritic Cell Cancer Vaccine Immunotherapy Market Regional Outlook
7.1 North America
7.2 India
7.3 South Korea
7.4 Japan
8. Global Dendritic Cell Cancer Vaccine Immunotherapy Clinical Trials Landscape
8.1 By Phase
8.2 By Patient Segment
8.3 By Company
8.4 By Country
8.5 By Cancer
9. Dendritic Cell Cancer Vaccine Immunotherapy - Dosage, Efficacy & Price Insight
9.1 Provenge
9.2 Apceden (Apceden-L, Apceden-O, Apceden-C, Apceden-P)
9.3 CreaVax RCC
10. Comparative Assessment of Provenge v/s other Therapeutics for Prostate Cancer
10.1 Provenge v/s Jevtana
10.1.1 Clinical Efficacy
10.1.2 Treatment Course & Dosage
10.1.3 Therapy Price Analysis
10.2 Provenge v/s Zytiga
10.2.1 Clinical Efficacy
10.2.2 Treatment Course & Dosage
10.2.3 Therapy Price Analysis
11. Global Dendritic Cell Vaccines Immunotherapy Clinical Pipeline By Company, Indication & Phase
11.1 Unknown
11.2 Research
11.3 Preclinical
11.4 Phase-0
11.5 Phase-I
11.6 Phase-I/II
11.7 Phase-II
11.8 Phase-II/III
11.9 Phase-III
12. Marketed Dendritic Cell Vaccines Immunotherapy Clinical Insight
12.1 CreaVax
12.2 Sipuleucel-T (Provenge)
12.3 Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical
13. Promising Future of Dendritic Cell Vaccines in Various Cancer
13.1 Dendritic Cell Vaccine in Stage-III Melanoma
13.2 Dendritic Cell Vaccine in Acute Myeloid Leukemia
13.3 Dendritic Cell Vaccine in Brain Tumor
14. Global Dendritic Cell Cancer Vaccine Market Dynamics
14.1 Favorable Market Parameters
14.2 Market Growth Challenges
15. Global Dendritic Cell Cancer Vaccine Market Future Outlook
15.1 Future Course for Market
15.2 Dendritic Cell Cancer Vaccine Technical Advancements
15.3 Availability of Target Patient Base for Dendritic Cell Cancer Vaccines
16. Competitive Landscape
16.1 3M Company
16.2 Activartis
16.3 Argos Therapeutics
16.4 Batavia Bioservices
16.5 Bellicum Pharmaceuticals
16.6 Creagene
16.7 DanDrit Biotech
16.8 DCPrime
16.9 Dendreon Corporation
16.10 Elios Therapeutics
16.11 ImmunoCellular Therapeutics
16.12 Immunicum
16.13 Kiromic
16.14 Medigene
16.15 Merck
16.16 Northwest Biotherapeutics
16.17 Glaxo Smith Kline
16.18 ImmunoCellular Therapeutics
16.19 SOTIO
16.20 Tella Incorporation
16.21 Theravectys
16.22 Vaxil BioTherapeutics
List of Figures
Figure 1-1: Milestones in the History of Dendritic Cell Cancer Vaccine Development
Figure 2-1: Dendritic Cell in Human Immune System
Figure 2-2: Effects of Tumor Cell in Dendritic Cell Dysfunction Leading to Tumor Progression
Figure 3-1: Process of Harvesting Dendritic Cell to Develop Vaccines
Figure 3-2: General Mechanism of Action of Dendritic Cell Vaccine
Figure 6-1: Global – Scope of Dendritic Cell Cancer Therapy Market by Ongoing Researches
Figure 6-2: Global – Scope of Dendritic Cell Cancer Therapy Market by Approved Advanced Therapies
Figure 6-3: Global – Scope of Dendritic Cell Vaccine Cancer Therapy Market by Later Phase Clinical Trials
Figure 6-4: Global – Number of Advanced Cancer Therapy Research Studies Funded by Non-Profit Organization
Figure 7-1: Global – Rocapuldencel-T Market Opportunity Analysis by Epidemiology of Renal Cell Carcinoma (Number of patients), 2020
Figure 7-2: India – Average Lung Cancer Prevalence per Year
Figure 7-3: India – Lung Cancer Prevalence by Stage (%), 2018
Figure 7-4: India – Apceden Market Opportunity by Epidemiology of Lung Cancer (Number of Patients), 2014-2020
Figure 7-5: India – Apceden Market Opportunity by Epidemiology of Ovarian Cancer (Number of Patients), 2014-2020
Figure 7-6: India – Apceden Market Opportunity by Epidemiology of Colorectal Cancer (Number of Patients), 2014-2020
Figure 7-7: India – Apceden Market Opportunity by Epidemiology of Prostate Cancer (Number of Patients), 2014-2020
Figure 7-8: South Korea – Renal Cell Carcinoma Population by Stage of Cancer, (%), 2018
Figure 7-9: South Korea – CreaVax RCC Market Opportunity by Renal Cancer Epidemiology (Number of Patients), 2014-2020
Figure 7-10: South Korea – Renal Cell Carcinoma Prevalence in Male Population by Number, 2014-2020
Figure 7-11: South Korea - Renal Cell Carcinoma Prevalence in Female Population by Number, 2014-2018
Figure 7-12: South Korea – Renal Cancer Prevalence by Gender, 2020
Figure 7-13: Japan – Epidemiology of Cancer by Gender (%), 2020
Figure 7-14: Japan – Epidemiology of Cancer (Number of Patients), 2020
Figure 7-15: Japan – Vaccell Market Opportunity by Epidemiology of Pancreatic Cancer by Gender (%), 2020
Figure 7-16: Japan – Vaccell market Opportunity by Epidemiology of Pancreatic Cancer (Number of Patients), 2020
Figure 7-17: Japan – Vaccell Market Opportunity by Epidemiology of Gall Bladder & Biliary Cancer by Gender (%), 2020
Figure 7-18: Japan – Vaccell Market Opprtunity by Epidemiology of Gall Bladder & Biliary Cancer (Number of Patients), 2018
Figure 7-19: Japan – Vaccell Potential Patient Base by New Incidences, 2020
Figure 8-1: Global - Dendritic Cell Cancer Vaccine Immunotherapy Clinical Pipeline by Phase (%), 2020 till 2026
Figure 8-2: Global - Dendritic Cell Cancer Vaccine Immunotherapy Clinical Pipeline by Phase (Number), 2020 till 2026
Figure 8-3: Global - Dendritic Cell Cancer Vaccine Immunotherapy Clinical Pipeline by Patient Segment (Number), 2020 till 2026
Figure 8-4: Global - Dendritic Cell Cancer Vaccine Immunotherapy Clinical Pipeline by Patient Segment (Number), 2020 till 2026
Figure 8-5: Global - Dendritic Cell Cancer Vaccine Immunotherapy Clinical Pipeline by Country (Number), 2020 till 2026
Figure 8-6: Global - Dendritic Cell Cancer Vaccine Immunotherapy Clinical Pipeline by Country (Number), 2020 till 2026
Figure 9-1: Provenge – Patent Issue & Expiration Year
Figure 9-2: Provenge: Efficacy on the Basis of Clinical Trials
Figure 9-3: Provenge – Number of Autologous CD54+ Activated Cells (Million)
Figure 9-4: Provenge – Dosage Administration (Minutes)
Figure 9-5: Provenge - Average Duration of Therapy
Figure 9-6: Provenge – Duration of Single Treatment Cycle & Full Treatment (Weeks), October’2020
Figure 9-7: Provenge – Price for 250 ml Supply & Price per ml of Intravenous Suspension (US$), October’2020
Figure 9-8: Provenge – Cost of Single Treatment Cycle & Cost of Full Treatment (US$), October’2020
Figure 9-9: Provenge – Company’s Expenditure in Drug Development & Therapy Market Value (US$ Billion)
Figure 9-10: Apceden – Median Progression-Free Survival in Patients with Solid Tumors (Number of Months)
Figure 9-11: Apceden – Median Progression Free Survival in Patients with Progressive Solid Tumors (Number of Months)
Figure 9-12: Apceden v/s Provenge – Adverse Side Effects (%), 2018
Figure 9-13: Apceden – Availability of Vial & Vials Required in Apceden Therapy
Figure 9-14: Apceden – Intervals Between Multiple Doses of Treatment
Figure 9-15: Apceden – Cost of Single Vaccine, 6 Vaccines & 12 Vaccines (US$/INR), October’2020
Figure 9-16: CreaVax RCC - Approval Analysis by Phase (Year)
Figure 9-17: CreaVax RCC - Treatment Course Duration (Weeks)
Figure 9-18: CreaVax RCC – Vial Composition Analysis (mL/Dose & Number of Cells/Dose)
Figure 9-19: South Korea - CreaVax RCC Patent Cost (US$)
Figure 9-20: South Korea – Pharmaceutical Compositions comprising Dendritic Cell Patent Cost (US$)
Figure 10-1: Provenge v/s Jevtana – Median Progression Free Survival (Months)
Figure 10-2: Provenge v/s Jevtana – Overall Survival (Months)
Figure 10-3: Provenge v/s Jevtana – Discontinuation of Treatment in Patients due to Adverse Effects (%)
Figure 10-4: Provenge v/s Jevtana – Average Treatment Cycles in Complete Therapy (By Number)
Figure 10-5: Provenge v/s Jevtana – Price Analysis (US$/Unit), 2020
Figure 10-6: Provenge v/s Jevtana – Price Analysis (US$/Infusion), 2018
Figure 10-7: Provenge v/s Jevtana – Average Treatment Cost Analysis (US$), 2020
Figure 10-8: Provenge v/s Zytiga – Median Progression Free Survival (Months)
Figure 10-9: Provenge v/s Zytiga – Therapy Cost Analysis (US$), 2020
Figure 14-1: Factors Favoring Global Dendritic Cell Cancer Vaccine Market
Figure 15-1: Future Drivers for Dendritic Cell Immunotherapy Market
Figure 15-2: Global – Dendritic Cell Cancer Vaccine Market Opportunity by Prevalence of Cancer (%)
Figure 16-1: Argos Therapeutics- Clinical Pipeline
Figure 16-2: Bellicum Pharmaceuticals Clinical Pipeline
Figure 16-3: DCPrime Clinical Pipeline
Figure 16-4: ImmunoCellular Therapeutics Clinical Pipeline
Figure 16-5: Immunicum Clinical Pipeline
Figure 16-6: Medigene Clinical Pipeline
Figure 16-7: Northwest Biotherapeutics Clinical Pipeline
Figure 16-8: SOTIO Clinical Pipeline
